Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
ranibizumab (lucentis) (2 trials)
Ischemia (Phase 1)
Macular Degeneration (Phase 4)
Retinal Vein Occlusion (Phase 1)
Trials (2 total)
Trial APIs (1 total)